Rx00140 - Lenalidomide


Name:
Lenalidomide
Rx ID:
Rx00140
Validation Level:
Phenomic Similarity:
0.504
Reference ID:
DB00480
Primary Indications:
Multiple myeloma; low-1-risk myelodysplastic syndromes; intermediate-1-risk myelodysplastic syndromes; mantle cell lymphoma
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Chronic lymphocytic leukemia; mantle cell lymphoma
Common Indications:
Multiple myeloma; transfusion dependant anemia; myelodysplastic syndromes; deletion 5 q cytogenetic abnormality; cytogenetic abnormalities
Pathways:
Integrated Pancreatic Cancer Pathway; Serotonergic synapse - Homo sapiens (human); Retrograde endocannabinoid signaling - Homo sapiens (human); Disease; Leishmaniasis - Homo sapiens (human); Selenium ...Click to show more
Drug Interactions:
Trastuzumab;
Food Interactions:
When given with a fatty meal, the extent of absorption is reduced.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00140
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
low-1-risk myelodysplastic syndromes myelodysplastic syndromes 1504 4237 1504 952.307 0 0.0
intermediate-1-risk myelodysplastic syndromes myelodysplastic syndromes 1504 4237 1504 952.307 0 0.0
multiple myeloma anemia 1528 3327 109590 16.91 0 0.0
mantle cell lymphoma anemia 35 84 109590 15.341 1.11E-26 3.56e-23

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
MULTIPLE MYELOMA MYELODYSPLASTIC SYNDROMES 1.17e-45 ABCB1, CDKN2A, CEBPA, CSF3R, CTLA4, CXCL12, CYP1A1, CYP1B1, CYP2C19, CYP2D6, CYP3A4, CYP3A5, EPHX1, ERCC1, ERCC2, ERCC5, FAS, FCGR2A, FLT3, GSTM1, GSTP1, GSTT1, HFE, HLA-C, HLA-DPB1, HLA-DQB1, HLA-DRB1, HPSE, IFNG, IL10, IL12A, IL1A, IL1B, IL1R1, IL1RN, IL2, IL4, IL4R, IL6, IL6R, IL8, JAK1, JAK3, KIR2DS4, KIR2DS5, KRAS, LIG4, LTA, MEFV, MPO, MTHFR, MYD88, NAT2, NQO1, NRAS, PDGFRA, PLK2, TAP1, TAP2, TERC, TERT, TGFB1, TLR2, TLR4, TNF, TP53, TYMS, VDR, VEGFA, XPA, XRCC1, XRCC3, XRCC5

Chemical, Pharmacological and Biological Annotations


ATC Code:
L04AX04
Brands:
Ladevina; Lenangio
Category:
Antineoplastic Agents
ChEBI ID:
63791
PubChem ID:
216326
KEGG Drug ID:
D04687
SMILE:
NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
InChI:
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
Classification:
Kingdom:
Organic Compounds
Superclass:
Heterocyclic Compounds
Class:
Isoindoles and Derivatives
Subclass:
Isoindolines
Indication:
Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndro...
Click to show more...
Pharmacodynamics:
Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory...
Click to show more...
Description:
Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeuti...
Click to show more...
Mechanism:
The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apopto...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.5145 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org